Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug delivery platforms, today announced that it has filed an
important new patent application in the United States describing the use of its
DehydraTECH(TM) technology for the delivery of antiviral drugs. According to
the update, the technology would potentially be used to improve treatment
options for viral infectious diseases including COVID-19, MERS, SARS,
influenza, herpes, hepatitis and AIDS. “Lexaria’s proprietary drug delivery
platform has already proven its effectiveness in the oral delivery of other
lipophilic drugs such as nicotine, cannabinoids, and more, with multi-fold
increases in both the rate and extent of bioabsorption,” Lexaria President John
Docherty said in the news release. “We hypothesize that, once detailed testing
begins, DehydraTECH will evidence improvements in the quantity and rapidity
with which certain antiviral drugs are able to reach the human bloodstream
after oral delivery. This has the potential to make a real contribution in the
fight against COVID-19.”
To view the full press release, visit http://ibn.fm/kjCBW
About Lexaria
Lexaria Bioscience Corp. is a global innovator in drug
delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes
the way API’s enter the bloodstream, promoting healthier ingestion methods,
lower overall dosing and higher effectiveness for lipophilic active molecules.
DehydraTECH increases bio-absorption; reduces time of onset; and can reduce
drug costs for orally administered bioactive molecules including nicotine,
vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and other molecules.
Lexaria has licensed DehydraTECH to multiple companies for use in various oral
application formats, including to a world-leading tobacco producer for the
development of smokeless, oral-based nicotine products. Lexaria operates a
federally licensed in-house research laboratory and holds a robust intellectual
property portfolio with 16 patents granted and over 60 patents pending
worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment